TORONTO, ON--(Marketwired - Mar 15, 2016) - Axxess Pharma Inc. (
Axxess Pharma's management felt this was the best time to conduct the reverse split with the expectation that this should be a sound capital structure for the company, to aggressively move forward into the future. This comes at a time when the company received over $87,000 in purchase orders in the first two months of 2016. These orders are coming in at record pace versus the same period in 2015. This surge in in orders was due to establishing strong relationships with new distributors that have a large health and wellness customer base. These customers are frequent buyers, which equates to residual sales.
Sales are anticipated to further accelerate throughout 2016 due to the second quarter launch of the much anticipated Ready To Drink (RTD), fat burning, protein shakes and protein bars. The RTD's are lactose free, gluten free and have less than one gram of sugar. The launch of the RTD's and protein bars was fueled by strong feedback of several large, national US retailers.
Dr. Bagi, President of Axxess Pharma, stated: "We are off to a great start this year. We have a strong capital structure, rising sales, new high performing distributors and the launch of the much anticipated RTD's and protein bars in the second quarter of this year. These new products have already generated high level of interest from our ECRM buyers." Dr. Bagi further stated, "Our line of meal replacement, protein-building products can satisfy both the high-performance athlete as well as persons just wishing to replace a meal with a product that will help them burn fat."
About Axxess Pharma Inc.:
Axxess Pharma Inc. is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain, - to optimal health management through improved nutritional supplements.
For more information, please contact Investor Relations at (973) 351-3868.
Safe Harbor Statement
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.